Riskpilot← Back to searchSign inGet full accessKariya Pharmaceuticals ApS
APSActiveCVR 39270684Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20181 employeeswww.kariyapharma.com
Revenue 2024
DKK -3,6M
-65% vs 2023
EBITDA margin
119.8%
+58% vs 2023
Equity ratio
55.7%
Financial strength
Net profit 2024
DKK -2,6M
+68% vs 2023
| Revenue | DKK -3,6M | -65% |
| EBITDA | DKK -4,3M | +58% |
| Net profit | DKK -2,6M | +68% |
| Total assets | DKK 2,3M | +12% |
| Equity | DKK 1,3M | +120% |
| Employees | 1 | — |
Legal name
Kariya Pharmaceuticals ApS
CVR number
39270684
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18. januar 2018
Share capital
DKK 48.285
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør, af en direktør sammen med bestyrelsens formand eller af den samlede bestyrelse.
Company purpose
Virksomhedens formål er forskning og udvikling af lægemidler samt dermed beslægtet virksomhed.
Address
Ole Maaløes Vej 3
Website
www.kariyapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | -6.325 | -1.493 | -2.712 | -13.798 | -10.223 | -3.625 |
| Staff expenses | -0 | -707 | -1.815 | -506 | -14 | -67 | -716 |
| EBITDA | 0 | -7.032 | -3.308 | -3.218 | -13.812 | -10.290 | -4.341 |
| Depreciation & amort. | -0 | -0 | -8 | -8 | -8 | -0 | -0 |
| EBIT | 0 | -7.032 | -3.316 | -3.226 | -13.820 | -10.290 | -4.341 |
| Net financials | 0 | -273 | -524 | -644 | -805 | -1.604 | -207 |
| Profit before tax | 0 | -7.304 | -3.840 | -3.869 | -14.625 | -11.893 | -4.548 |
| Tax | -0 | -0 | -1.633 | -614 | -619 | -3.871 | -1.948 |
| Net profit | 0 | -7.304 | -2.207 | -3.255 | -14.006 | -8.023 | -2.599 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 0 | 3.179 | 1.683 | 1.052 | 2.205 | 2.051 | 2.304 |
| Equity | 0 | -7.304 | -9.511 | -12.726 | -26.732 | -6.388 | 1.284 |
| Long-term debt | 0 | 10.268 | 10.782 | 11.321 | 11.887 | 0 | 0 |
| Short-term debt | 0 | 215 | 413 | 2.458 | 17.050 | 8.440 | 1.020 |
| Total debt | 0 | 10.483 | 11.195 | 13.778 | 28.937 | 8.440 | 1.020 |
EBITDA margin
-434096700.0%
This company
15.8%
Market median
-2747447568% vs market
20182024
Equity ratio
55.7%
This company
38.2%
Market median
+46% vs market
20182024
Return on equity
-202.5%
This company
18.4%
Market median
-1201% vs market
20182024
Net profit margin
-259941200.0%
This company
8.1%
Market median
-3209150717% vs market
20182024
Asset turnover
-1.57×
This company
1.12×
Market median
-240% vs market
20182024
Debt / equity
0.79×
This company
0.62×
Market median
+27% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-18 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CH Management | Management | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2025 | |
JUMIKA Holdings ApS | Company | 33.3% | 33.3% | 2018 |
| Individual | 10.0% | 10.0% | 2023 | |
Thomsen Pharma ApS | Company | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JUMIKA Holdings ApS
Kariya Pharmaceuticals ApS Board members of Kariya Pharmaceuticals ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christian Hölscher | Management | 0 companies |
| Mikael Søndergaard Thomsen | Board of Directors | 0 companies |
| Ian Rodney Laquian | Chairman | 0 companies |
| John Connell | Board of Directors | 0 companies |
| Claus Elsborg Olesen | Board of Directors | 0 companies |